-
1Academic Journal
Συγγραφείς: M. I. Sokolova, V. I. Pavlova, A. O. Guz, A. V. Simonov, М. И. Соколова, В. И. Павлова, А. О. Гузь, А. В. Симонов
Πηγή: Head and Neck Tumors (HNT); Том 14, № 3 (2024); 41-48 ; Опухоли головы и шеи; Том 14, № 3 (2024); 41-48 ; 2411-4634 ; 2222-1468
Θεματικοί όροι: общая выживаемость, squamous cell carcinoma of the oropharynx, expression of р16, expression of programmed death-ligand 1, overall survival, плоскоклеточный рак ротоглотки, экспрессия р16, экспрессия лиганда рецептора программируемой клеточной гибели 1
Περιγραφή αρχείου: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/1003/641; Global Burden of Disease Cancer. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2019;5(12):1749–68. DOI:10.1001/jamaoncol.2019.2996; Adjei Boakye E., Buchanan P., Hinyard L. et al. Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma. JAMA Otolaryngolog Head Neck Surg 2018;144(8):727–37. DOI:10.1001/jamaoto.2018.0993; Faisal M., Le N.S., Grasl S. et al. Survival outcome in true carcinoma of unknown primary (tCUP) with p16 + сervical metastasis. Int Arch Otorhinolaryngol 2023(27):e687–93. DOI:10.1055/s-0042-1759575; Conway A.M., Mitchell C., Kilgour E. et al. Molecular characterisation and liquid biomarkers in carcinoma of unknown primary (CUP): taking the “U” out of “CUP.” Br J Cancer 2019;120(2):141–53.; Pavlidis N., Pentheroudakis G. Cancer of unknown primary site. Lancet 2012;379(9824):1428–35. DOI:10.1016/S0140-6736(11)61178-1; Sivars L., Bersani C., Grün N. et al. Human papillomavirus is a favourable prognostic factor in cancer of unknown primary in the head and neck region and in hypopharyngeal cancer. Mol Clin Oncol 2016;5(6):671–4. DOI:10.3892/mco.2016.1050; Rassy E., Nicolai P., Pavlidis N. Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. Head Neck 2109;41(10):3700–11. DOI:10.1002/hed.25858; Müller von der Grün J., Tahtali A., Ghanaati S. et al. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site – current status and challenges. Radiat Oncol 2017;12(1):82. DOI:10.1186/s13014-017-0817-9; Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915–28. DOI:10.1016/S0140-6736(19)32591-7; Eskander A., Ghanem T., Agrawal A. et al. AHNS series: do you know your guidelines? Guideline recommendations for head and neck cancer of unknown primary site. Head Neck 2018;40(3):614–21. DOI:10.1002/hed.25026; Ren J., Yang W., Su J. et al. Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region Int J Cancer 2019;145:1465–74.; Kansy B.A., Concha-Benavente F., Srivastava R.M. et al. PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res 2017;77(22):6353–64. DOI:10.1158/0008-5472.CAN-16-3167; Mandal R., Şenbabaoğlu Y., Desrichard A. et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1(17):e89829. DOI:10.1172/jci.insight.89829; Cohen E.E.W., Bell R.B., Bifulco C.B. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019;7(1):184. DOI:10.1186/s40425-019-0662-5; Binnewies M., Roberts E.W., Kersten K. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24(5):541–50. DOI:10.1038/s41591-018-0014-x; Elbehi A.M., Anu R.I., Ekine-Afolabi B., Cash E. Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncol 2020;109:104977. DOI:10.1016/j.oraloncology.2020.104977; Patel J.J., Levy D.A., Nguyen S.A. et al. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinomaSystematic review and meta-analysis. Head Neck 2020;42(4):774–86. DOI:10.1002/hed.26036; Haratani K., Hayashi H., Takahama T. et al. Clinical and immune profiling for cancer of unknown primary site. J Immunother Cancer 2019;7(1):25. DOI:10.1186/s40425-019-0720-z; Dong P., Xiong Y., Yue J. et al. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol 2018;8:386. DOI:10.3389/fonc.2018.00386; Simsek M., Tekin S.B., Bilici M. Immunological agents used in cancer treatment. Eurasian J Med 2019;51(1):90–4. DOI:10.5152/eurasianjmed.2018.18194; Alsahafi E., Begg K., Amelio I. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 2019;10(8):540. DOI:10.1038/s41419-019-1769-9; Hemminki K., Pavlidis N., Tsilidis K.K. et al. Age-dependent metastatic spread and survival: cancer of unknown primary as a model. Sci Rep 2016;6:23725. DOI:10.1038/srep23725; Cohen E.E., LaMonte S.J., Erb N.L. et al. American Cancer Society head and neck cancer survivorship care guideline. CA Cancer J Clin 2016;66(3):203–39. DOI:10.3322/caac.21343; Cummings M.A., Ma S.J., Van Der Sloot P. et al. Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry. Ann Transl Med 2021;9(4):284. DOI:10.21037/atm-20-4631; Reuschenbach M., Tinhofer I., Wittekindt C. et al. A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany. Cancer Med 2019;8(4):1908–18. DOI:10.1002/cam4.2039; Sprave T., Rühle A., Hees K. et al. Radiotherapeutic management of cervical lymph node metastases from an unknown primary site – experiences from a large cohort treated with modern radiation techniques. Radiat Oncol 2020;15(1):80. DOI:10.1186/s13014-020-01529-z; Chung C.H., Zhang Q., Kong C.S. et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 2014;32(35):3930–8. DOI:10.1200/JCO.2013.54.5228; https://ogsh.abvpress.ru/jour/article/view/1003